Long-acting cabotegravir plus rilpivirine (Cabenuva) achieved superior viral suppression vs daily oral antiretroviral therapy at 6months in treatment-experienced people with HIV and detectable viremia in the phase 3b CROWN trial.
|Videos|April 29, 2019
Novel Curative Strategy for HIV
Author(s)Contagion® Editorial Staff
Ben Berkhout, MD, PhD, discusses his work on the development of a novel curative strategy for HIV-1 infected individuals.
Advertisement
?rel=0" Segment Description: Ben Berkhout, MD, PhD, discusses his work on the development of a novel curative strategy for HIV-1 infected individuals.
Interview transcript (modified slightly for readability):
Ben Berkhout, MD, PhD: We work on the development of a novel curative strategy for HIV-1 infected individuals. As you know, we have many drugs that we can use to block the virus replication and these drugs are wonderful, they have saved many lives.
But what we are trying to establish is a new therapy that will be a 1 shot therapy, with a long-term curative effect. Because all of these drugs are wonderful, but you have to take them every day of your life, so that’s what we want to change, and this is based on the CRISPR-cas technology.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
SubscribeAdvertisement
Related to this article
Pritelivir (Hovilpri) healed all lesions by day 28 in 63% of immunocompromised adults with refractory HSV versus 34% with investigator's choice in the phase 3 PRIOH-1 trial.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Demonstrating a diagnostic test works is no longer enough. Clinicians and laboratories also need evidence on how to adopt it in everyday practice. Andrea Prinzi, PhD, MPH, SM(ASCP), explains how implementation science can help infectious disease and clinical microbiology teams turn evidence into routine care.
Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Advertisement
Advertisement